#United States #Phoenix #Cancer Immunotherapy #SITC #late-breaking abstracts

SITC 2026: Late-Breaking Abstracts and Press Briefing

The Society for Immunotherapy of Cancer (SITC) has generated significant excitement with the announcement of nearly 1,200 abstract submissions for its upcoming 41st Annual Meeting. This event will take place from November 4 to 8, 2026, in Phoenix, Arizona, alongside virtual participation options. Among the most anticipated aspects of the conference are the late-breaking abstracts (LBA), which contain crucial, up-to-the-minute data from clinical trials involving human subjects.

Prominent Abstracts and Key Presentations

The organization has unveiled the titles and authors of the selected late-breaking abstracts, highlighting noteworthy advancements in cancer immunotherapy. These abstracts will be presented during a special session, showcasing innovative approaches to tackle various cancer types through immune-based therapies. Here are some prominent presentations scheduled for the event:

1. Adoptive Transfer of T cells Engineered with Mutant p53-specific TCRs for Metastatic Solid Epithelial Cancers
- Presenter: Sanghyun Kim, PhD – National Cancer Institute

2. Adaptive Anti-CAR Immunity's Impact on GD2-CAR T Cell Therapy Durability in Diffuse Midline Glioma
- Presenter: Kevin Reynolds, MD – Stanford Cancer Institute

3. OBX-115 TIL Cell Therapy Efficacy in Advanced Melanoma
- Presenter: Rodabe Amaria, MD – The University of Texas MD Anderson Cancer Center

4. Adoptive Immunotherapy Following Cancer Neoantigen Vaccination in Glioblastoma Patients
- Presenter: Patrick Grogan, MD – Moffitt Cancer Center

5. Oncolytic Adenoviruses Promoting Durable Antitumor Immunity in Brain Tumors
- Presenter: Hong Jiang, PhD – The University of Texas MD Anderson Cancer Center

These examples represent merely a fraction of the innovative research that will be shared, all of which contribute significantly to the evolving landscape of cancer treatment.

Virtual Press Briefing Details

To complement the announcements, SITC will host a virtual press briefing on November 4, 2026, from 12:00 to 1:30 PM MT. This session aims to engage the media and provide insights into the most significant advances in cancer immunotherapy research presented at the annual meeting. Participating journalists can submit questions for up to three minutes following each presentation.

Registration is essential for press members wishing to attend the briefing. Interested individuals can sign up at the SITC website. Those who complete the registration process will receive further instructions on how to access the briefing.

For more in-depth information regarding the SITC 2026 Annual Meeting and related media policies, please refer to the official website at sitcancer.org/2026.

About SITC

Founded in 1984, the Society for Immunotherapy of Cancer is dedicated to improving cancer patient outcomes through the advancement of cancer immunotherapy and immunology. The organization comprises a diverse group of professionals including researchers, clinicians, and industry leaders focused on enhancing the scientific community's knowledge and collaborative efforts in this critical field. Through various educational initiatives, SITC seeks to make effective cancer cures a reality for patients worldwide.

Be sure to follow SITC on various social platforms like X, LinkedIn, Bluesky, Facebook, and YouTube to stay updated on their latest developments and events.